Week in Review: Zai Lab Targets $1 Billion Valuation in Planned US IPO

Deals and Financings - Zai Lab has selected investment bankers for a US IPO with a rumored goal of raising $150 million and a $1 billion company valuation;  - Hangzhou Just Biotherapeutics (Just China) completed a $57 million Series B funding to develop a portfolio of affordable innovative and biosimilar products; - New Horizon Health, a Beijing-Hangzhou company developing early-stage cancer screening products, raised $20 million in a B round; - Shanghai Fosun Pharma is competing with Shanghai Pharma Holding to acquire a $600-$700 million stake in Atlanta's Arbor Pharma; - Biocept, a San Diego diagnostics company, completed a $2.2 million private placement from Ally Bridge, who will help the company with a China strategy; - Shenzhen Salubris negotiated a tech transfer with the US National Institutes of Health for a potential liver cancer drug; - HitGen of Chengdu began a multi-target, multi-year drug discovery collaboration with LEO Pharma A/S, a Danish dermatology company; Company News - Shanghai Pharma signed a MOU with DHL Supply Chain to prepare for a global expansion and optimize its current China pharma distribution network; Trials and Approvals -Dennis Lo, PhD, founder of Hong Kong cancer screening company Cirina, led a successful three-year test among 20,000 men for nasopharyngeal cancer, showing the value of early screening. Stock Symbols: (SHA: 600196; HK: 2196) (SHA: 601607) (NSDQ: BIOC) (SZE: 2294) Share this with colleagues: // //